Patients who have rickets experience a softening and weakening of their bones traced to a vitamin deficiency. In a rare, inherited form of the disease, vitamin D supplements don’t work.
Ultragenyx (NASDAQ: RARE) has received FDA approval for a drug to treat patients who have this form of the disease, called X-linked hypophosphatemia (XLH). The Novato, CA-based company said Tuesday that the regulatory approval for its drug, burosumab (Crysvita), covers adults as well as children over the age of 1. The FDA’s nod, which came following a priority review given to drugs developed to offer significant improvement in the treatment… Read more »
UNDERWRITERS AND PARTNERS